Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Nanovation Therapeutics Inc. currently manages 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 2 distinct art units, indicating a focused but slightly divided regulatory path. The portfolio involves 3 distinct examiners, matching the total count of pending actions. This alignment suggests that each examiner is currently reviewing an individual application. Practitioners should prepare for varied feedback across the different departments involved in these proceedings.
AZPURU, CARLOS A is identified as the busiest examiner for this portfolio, currently handling 1 pending office action. This distribution confirms that the workload is not concentrated under a single official. The presence of 3 distinct examiners for these matters ensures that each case receives individual attention from a unique official. Navigating 2 distinct art units requires a strategy that accounts for the specific examination standards of each department while managing the 3 pending office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AZPURU, CARLOS A | 1 | 83.8% | +10.7% |
| BRADY, KRISTEN WEEKS | 1 | 0.0% | +0.0% |
| LIPPERT, JOHN WILLIAM | 1 | 58.2% | +40.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18650569 | MRNA DELIVERY METHOD AND COMPOSITION THEREOF | AZPURU, CARLOS A | — |
| 18442431 | Method for the Synthesis of Ionizable Lipids Using a Doubly Alkylated Intermediate | BRADY, KRISTEN WEEKS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18564780 | Method for Producing an Ionizable Lipid | LIPPERT, JOHN WILLIAM | 19d |
| 18650569 | MRNA DELIVERY METHOD AND COMPOSITION THEREOF | AZPURU, CARLOS A | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18650569 | MRNA DELIVERY METHOD AND COMPOSITION THEREOF | AZPURU, CARLOS A | 1617 | §103§112Other | Non-Final OA | — | Pending | Apr 30, 2024 |
| 18442431 | Method for the Synthesis of Ionizable Lipids Using a Doubly Alkylated Intermediate | BRADY, KRISTEN WEEKS | — | §101§112 | Non-Final OA | — | Pending | Feb 15, 2024 |
| 18564780 | Method for Producing an Ionizable Lipid | LIPPERT, JOHN WILLIAM | 1615 | §103 | Final Rejection | 19d | Pending | Nov 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial